Navigation Links
Repligen Reports First Quarter Fiscal Year 2010 Financial Results
Date:8/6/2009

on will receive either RG2417 or a placebo twice a day for eight weeks. The study is designed to assess the safety and efficacy of RG2417 on the symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression of Change in Bipolar Disorder scale (CGI-BP-C). In March, Repligen exclusively licensed worldwide rights to a patent application from McLean Hospital for the use of uridine in the treatment of patients with bipolar disorder. If issued, the patent would remain in force until at least 2025. More than five million adults worldwide have bipolar disorder.

HDAC Inhibitors for Friedreich's Ataxia

We are currently developing inhibitors of histone deacetylase enzymes (HDACs) for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia. Preclinical studies have shown that specific HDAC inhibitors increase production of the protein frataxin which may have the potential to arrest disease progression in patients with Friedreich's ataxia. We have identified several potential clinical candidates and are further characterizing these leads in preclinical models for their pharmacologic, toxicologic and pharmacodynamic profiles.

Quarterly Conference Call

Repligen will host a conference call and webcast on Thursday, August 6th at 10:00 a.m. EDT, to review financial results. This call can be accessed via Repligen's website at www.repligen.com or by calling (800) 638-4930 for domestic calls and (617) 614-3944 for international calls. Participants must provide the following passcode: 65889469.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global Resorcinol Market ... industry insights on the global resorcinol industry. The report highlights the various growth ... market scenarios and analysis of primary and secondary inputs from the existing players ...
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of ... 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the public ... daily lives. This unique exhibit also features a birthing center for fair goers to ...
(Date:7/30/2015)... France and Dallas, TX, USA (PRWEB) , ... ... ... of innovative nano and microsystems, has appointed Francois Vieillard as Sales & Marketing ... Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business ...
(Date:7/30/2015)... San Diego , CA (PRWEB) , ... July ... ... Biopharma, announced the successful completion of a field clinical study of its canine ... being developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... 2 Sicel Technologies, Inc., announced today that ... bankruptcy. Effective August 31, 2010, Paul McDaniel became ... the company. Currently, Sicel,s operations are continuing and ... returned to work.Media Contact: Lisa P. Sumner, Esq., ...
... Cell Treatments -- SHENZHEN, China, Sept. 2 /PRNewswire-Asia/ -- ... ... ... // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... growing interest in using nanoparticles for everything from ... the need to understand the environmental, health and ... at the National Institute of Standards and Technology ... nanocrystals that will enable studies of certain physical ...
Cached Biology Technology:New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 2New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 3New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 4New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 5New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 6New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 7New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 8The perfect nanocube: Precise control of size, shape and composition 2
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... typically associated with trees; they can take centuries to grow. However, ... in the Proceedings of the National Academy of Sciences ... growing faster than they have in the past 225 years. The ... to ,climate change. For more than 20 years forest ecologist ...
... day care workers and kindergarten teachers tend to offer young humans ... sharing just comes naturally. In fact, according to a pair ... like bonobos never seem to learn how not to share. ... by physical aggression if necessary. While chimps will share as youngsters, ...
... one day walk on walls, like Spider-Man? A palm-sized device ... adhesive bond just might make it possible. The rapid ... gloves that stick and unstick to walls, or Post-it-like notes ... chemical and biomolecular engineering, who invented the device with Michael ...
Cached Biology News:Ecologists discover forests are growing faster 2Ecologists discover forests are growing faster 3'Peter Pan' apes never seem to learn selfishness 2'Peter Pan' apes never seem to learn selfishness 3New adhesive device could let humans walk on walls 2
...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Biology Products: